The first fully functional lab-grown human organ is successfully transplanted into a patient before 2030.

Question

Six frontier AI models put this at 11% by 12 Oct 2031. Full reasoning from every model.

WillHappen.ai · Accepted Answer

11% — the median of 6 frontier models, resolving by 2031-10-12.

Answer

Gemini (Google): 8% — Scaling whole vascularized solid organs through human trials cannot clear FDA safety hurdles within a three-year window. Simple bioengineered tissues like skin or bladders exist, but complex solid organs (liver, kidney, heart) lack mature microvasculature. Any human trial requires multi-year IND approval, surgical implantation, and post-op follow-up that cannot fit before Dec 2029. Xenotransplantation is absorbing the bulk of clinical transplant funding and attention, relegating de novo lab organs to pre-clinical models.

Answer

Claude (Anthropic): 5% — Depends on whether whole-organ bioengineering clears vascularization and immune hurdles for human transplant by 2030. Current progress is limited to bladders, tracheas, and bioengineered scaffolds with partial cell seeding, not fully lab-grown vascularized organs like kidneys or hearts. No human trials of a fully lab-grown solid organ transplant exist as of 2026; animal models for vascularized organs remain early-stage. A breakthrough in 3D bioprinting with functional vasculature could accelerate this, but regulatory and safety timelines for first-in-human trials typically take years…

Answer

GPT (OpenAI): 38% — It hinges on whether a vascularized, patient-ready organ can clear first-in-human safety and transplant follow-up by 2029. Hospitals, sponsors, regulators and transplant teams must complete GMP manufacture, an IND/CTA and a first-in-human operation before 2030. Engineered bladders, tracheas and skin set partial precedents, but durable whole-organ vascularization and function remain unproven at scale. A 2027-28 approved trial of a lab-grown kidney, liver segment or heart would materially raise the odds.

Answer

Grok (xAI): 12% — A complex bioengineered organ must finish animal work and receive first-in-human approval by late 2029. No IND or ethics-cleared trial for a fully lab-grown kidney, liver or heart exists today; GLP tox plus manufacturing scale-up typically consume 4–6 years. Bladder grafts (Wake Forest 2006) remain the only clinical precedent and are structurally far simpler; vascularized solid organs have never left large-animal studies. Xenotransplant progress (pig kidneys 2024–26) would not satisfy the criterion and could divert funding and regulatory attention away from purely lab-grown constructs.

Answer

DeepSeek (DeepSeek): 12% — Whole lab-grown solid organs need vascularized scaffolds that no group has yet transplanted into a human. Bladder and trachea substitutes were transplanted years ago, but those are simple hollow structures, not functional solid organs. Any solid organ requires a Phase I trial, FDA clearance, and years of follow-up; no such trial is enrolling as of 2026. The 2030 deadline leaves roughly four years, far shorter than the decade-plus typical bench-to-bedside timeline for complex biologics.

Answer

Qwen (Alibaba): 9% — Vascularization of solid organs remains unsolved; even simple tissue-engineered bladders have stalled in trials for 15+ years. Atala's bladder trials at Wake Forest have produced limited, inconsistent results since ~2006; no complex solid organ (kidney, liver, heart) has cleared preclinical… FDA approval alone adds 3-5 years post-trial; no tissue-engineered whole organ is currently in Phase III or even Phase II as of 2026. A development that would shift this: a team demonstrating a perfusable, transplantable kidney or liver in large-animal models by 2027—but none has yet.

The first fully functional lab-grown human organ is successfully transplanted into a patient before 2030.

Cedars-Sinai reports that microgravity improved the production of stem-cell-derived structures from the CRS-35 mission experiments.

Genetic editing creates a distinct human subspecies before 2050.

A human life expectancy surpasses 150 years through medical intervention before 2050.

Mount Sinai's CRS-35 tissue model experiment yields publishable data on microgravity-induced aging or functional changes.